Munich, Germany March 2, 2009 >> Genomatix Software, a leading provider of complete solutions for the analysis of Next Generation Sequencing (NGS) data, announced today that Boehringer Ingelheim Pharma GmbH & Co. KG installed a Genomatix Mining Station and a Genomatix Genome Analyzer at its Pharma Research Center in Biberach, Germany. These systems deliver the only complete and integrated analysis solution for NGS data, from the raw data generated by the sequencer, to a molecular level understanding of the biology being studied.
Klaus May, Chief Business Officer at Genomatix says: "Adding the competent and well respected company Boehringer Ingelheim to our growing customer list for our NGS analysis systems makes us very proud. It confirms that Genomatix leading edge technology is going the right direction. More than a decade of research and development allows us to be at the forefront of the exciting NGS market. We are prepared today for the data avalanche to be expected from future generations of next generation sequencers "
The Genomatix Mining Station (GMS) is based on a proprietary genomic pattern recognition paradigm, or GenomeThesaurus, which allows for input of raw sequence reads plus optional quality files from any deep sequencing hardware. It provides ultra fast mapping of sequences of any length (starting from 8bp) with no practical limits on the number of point mutations and/or insertions and deletions that can be taken into account during the mapping process. Depending on the nature of the experiment, the GMS can provide SNP detection and genotyping, copy number analysis, and small RNA analysis. For ChIPseq data, the GMS delivers clustering and peak finding, and performs automated binding pattern identification. For RNAseq experiments, normalized expression values are calculated at the exon and transcript level. A special GenomeThesaurus is also provided for potential splice junctions, which allows for splice junction analysis an
|Contact: Klaus May|
Genomatix Software GmbH